Immuneering Corporation
IMRXNASDAQHealthcare● Active
$3.93
$-0.34(-7.96%)
Market Cap$142668188
P/E Ratio—
52W High$10.08
52W Low$1.66
Immuneering Corporation (IMRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.21
Est. -$0.30 · +30.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
IMRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.26 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.30 | -$0.21 | +30.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 6, 2026 | -$0.31 | -$0.18 | +41.9% | — | — | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.37 | -$0.38 | -2.7% | — | — | — |
| — Q3 FY2025 | Aug 13, 2025 | -$0.40 | -$0.40 | +0.0% | — | — | — |
| ▼ Q2 FY2025 | May 5, 2025 | -$0.41 | -$0.42 | -2.4% | — | — | — |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.42 | -$0.58 | -38.1% | — | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.54 | -$0.49 | +9.3% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.21
EPS Est.
-$0.30
EPS Surpr.
+30.0%
Revenue
—
Q1 FY2026
Mar 6, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.31
EPS Surpr.
+41.9%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.38
EPS Est.
-$0.37
EPS Surpr.
-2.7%
Revenue
—
Q3 FY2025
Aug 13, 2025
EPS Actual
-$0.40
EPS Est.
-$0.40
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2025
May 5, 2025Miss
EPS Actual
-$0.42
EPS Est.
-$0.41
EPS Surpr.
-2.4%
Revenue
—
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$0.58
EPS Est.
-$0.42
EPS Surpr.
-38.1%
Revenue
—
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.49
EPS Est.
-$0.54
EPS Surpr.
+9.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.46 | $-0.46 | $-0.46 | 2 |
| Q3 FY2027 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Q2 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q1 FY2027 | $-0.36 | $-0.36 | $-0.36 | 2 |
| Q4 FY2026 | $-0.34 | $-0.34 | $-0.34 | 2 |
| Q3 FY2026 | $-0.36 | $-0.31 | $-0.27 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +30.0% | $5.14 | $5.16 | +0.39% |
| ▲ Q1 FY2026 | Mar 6, 2026 | +41.9% | $4.98 | $5.33 | +7.03% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -2.7% | $6.74 | $6.62 | -1.78% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +0.0% | $3.25 | $3.22 | -0.92% |
| ▼ Q2 FY2025 | May 5, 2025 | -2.4% | $1.24 | $1.25 | +0.81% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -38.1% | $1.68 | $1.65 | -1.79% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +9.3% | $1.83 | $1.71 | -6.56% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +7.8% | $1.22 | $1.24 | +1.64% |
Q2 FY2026+0.39%
Report Date
May 15, 2026
EPS Beat/Miss
+30.0%
Price Before
$5.14
Price After
$5.16
Q1 FY2026+7.03%
Report Date
Mar 6, 2026
EPS Beat/Miss
+41.9%
Price Before
$4.98
Price After
$5.33
Q4 FY2025-1.78%
Report Date
Nov 12, 2025
EPS Beat/Miss
-2.7%
Price Before
$6.74
Price After
$6.62
Q3 FY2025-0.92%
Report Date
Aug 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$3.25
Price After
$3.22
Q2 FY2025+0.81%
Report Date
May 5, 2025
EPS Beat/Miss
-2.4%
Price Before
$1.24
Price After
$1.25
Q1 FY2025-1.79%
Report Date
Mar 20, 2025
EPS Beat/Miss
-38.1%
Price Before
$1.68
Price After
$1.65
Q4 FY2024-6.56%
Report Date
Nov 13, 2024
EPS Beat/Miss
+9.3%
Price Before
$1.83
Price After
$1.71
Q3 FY2024+1.64%
Report Date
Aug 6, 2024
EPS Beat/Miss
+7.8%
Price Before
$1.22
Price After
$1.24
Avg Beat Reaction+0.32%
Avg Miss Reaction-0.92%
Beat Rate5 / 8 quarters
Largest Move+7.03% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMRX ends December
Immuneering Corporation (IMRX) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.21 — beating the analyst consensus of $-0.30 by +30.0%. IMRX has beaten EPS estimates for 2 consecutive quarters. The next IMRX earnings date is expected around September 1, 2026.
Each quarter, investors track IMRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMRX earnings · 5 questionsImmuneering Corporation's next earnings report is expected around September 1, 2026. IMRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMRX historically reports after market close (AMC).
IMRX earnings datewhen is IMRX earningsIMRX next earnings datewhen does IMRX report earningsIMRX earnings calendar
▸ Source: FMP · Immuneering Corporation SEC filings · US GAAP · Immuneering Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026